Chromosomal translocations involving the Mixed-Lineage Leukaemia (MLL) gene underlie many human leukaemias and MLL rearrangements are found in both acute myelogenous and acute lymphoblastic leukaemias. To assess the functionally relevant haematopoietic cell contexts for MLL fusions to be tumorigenic, we have generated different lines of mice in which de novo Mll-associated translocations occur. In these models, reciprocal chromosomal translocations occur by means of Cre-loxPmediated recombination (translocator mice) in different cells of the haematopoietic system (namely haematopoietic stem cells, semi-committed progenitors or committed T or B cells). Translocations between Mll and Enl cause myeloid neoplasias, initiating in stem cells or progenitors while no tumours arose when the translocation was restricted to the B-cell compartment. Despite the absence of tumorigenesis, Mll-Enl translocations did occur and Mll-Enl fusion mRNA was expressed in B-cell-restricted translocators. A permissive cellular environment is therefore required for oncogenicity of Mll-associated translocations since the occurrence of Mll-Enl does not promote unrestricted proliferation in all haematopoietic cellular contexts, consistent with a specific instructive role of the MLL-fusion proteins in leukaemogenesis.
Introduction
Chromosomal translocations are primary events in many human leukaemias, sarcomas and perhaps in epithelial tumours, where mainly non-reciprocal events are found. There are multifarious translocations found in leukaemias/lymphomas, typically transcription regulators (Rabbitts, 1991) , but among the most frequent targets of translocations in human leukaemias is the mixed-lineage leukaemia (MLL) gene, located on chromosome 11, band q23 Daser and Rabbitts, 2004) . MLL gene abnormalities are found in both childhood (B10% of all paediatric leukaemias) and adult leukaemias (B5% of acute leukaemias; Pui et al., 2002b; Pui and Campana, 2007) . Around 5-10% of all MLL-associated leukaemias are cancer therapy related, arising, regardless of the primary cancer type, as a side effect of treatment with topoisomerase II targeting drugs or of other treatments including radiotherapy (Felix, 2001; Huret et al., 2001; Bloomfield et al., 2002; Pui et al., 2002a) .
MLL encodes a complex protein and, following chromosomal translocations, many different MLL fusions occur (more than 60) with partners that represent structurally heterogeneous proteins (Huret et al., 2001; Ayton and Cleary, 2003; Daser and Rabbitts, 2004) . The most frequent partners are AF4, AF9 and ENL (respectively fused in translocations t(4;11), t(9;11), t(11,19)), which taken together these fusions account for over 60% of leukaemia cases with 11q23 translocations. Unlike most recurrent translocations, MLL rearrangements are found in both acute myelogenous leukaemia and acute lymphoblastic leukaemia. The resulting MLL fusion proteins, however, are associated with haematopoietic tumours of different lineages: while MLL-AF4 in humans typically manifests as a B-cell acute lymphoblastic leukaemia (acute lymphoblastic leukaemia phenotype), MLL-AF9 is predominantly found in acute myelogenous leukaemias, and MLL-ENL in both acute lymphoblastic leukaemia and acute myelogenous leukaemias Daser and Rabbitts, 2004) . This unusual fact suggests that the fusion product has direct effects on cellular differentiation (non-instructive vs instructive models of MLL-fusion-mediated leukaemogenesis; Daser and Rabbitts, 2004) .
These questions have been explored further by generating different mouse lines where conditional de novo Mll-Enl or Mll-Af9 reciprocal chromosomal translocations occur (translocator mice; Collins et al., 2000; Forster et al., 2003) using Cre-mediated inter-chromosomal recombination. Different lineage-specific Cre genes have been employed to achieve cell-specific translocations and we have found that all the translocator mice involving Mll-Enl fusion, except those where the Cre recombinase was expressed from the CD19 gene, developed leukaemia. However, despite the absence of tumorigenesis in Mll-Enl; CD19-Cre mice, Mll-Enl chromosomal translocations do occur and the Mll-Enl fusion transcript was present. We conclude that Mll-Enl cannot promote tumorigenesis in every cellular context in haematopoiesis, therefore mitigating against a non-instructive role for the fusion protein in leukaemia in all settings.
Results and discussion
Cohorts of 20 mice were established with Mll plus Enl or Mll plus Af9 loxP alleles and carrying the different lineage-specific promoter-Cre alleles (Lmo2, generally expressed in early, non-differentiated haematopoietic cells; Rag1 expressed in the early stages of both lymphoid lineage; Lck, expressed in the T-cell lineage; and CD19, expressed in the B-cell lineage; McCormack et al., 2003) . The different mouse groups were monitored for possible adverse effects and animals were killed at the first sign of illness. As seen in Figure 1 , within the first 120 or 180 days respectively 100% of the Mll-Enl translocator mice with the Lmo2 or Rag1 controlled expression of Cre had died or been killed due to the incidence of leukaemia. As seen before for the Mll; Enl; Lmo2-Cre mice , post-mortem examination of these leukaemic groups (Lmo2-, Rag1-and Lck-Cre translocators) revealed a myeloid lineage malignancy typified by splenomegaly, swollen lymph nodes and pale liver. By the Bethesda classification of non-lymphoid tumours (Kogan et al., 2002) , these mice developed a myeloproliferative-like myeloid leukaemia. The Mll; Enl; Lck-Cre translocator group showed a relative long lag before the appearance of leukaemia. As described previously, out of the 20 Mll; Enl; Lck-Cre mice, 18 developed haematopoietic neoplasms within 550 days (Drynan et al., 2005) . Unlike the uniform finding of myeloproliferative-like myeloid leukaemia in the Lmo2-and Rag1-Cre translocators, the Mll; Enl; Lck-Cre group showed also some mice with T-cell neoplasias (small T-cell lymphoma; Drynan et al., 2005) .
Unlike the Mll-Enl translocators with Lmo2-Cre, Rag1-Cre or Lck-Cre, no haematological malignancies were observed in the mice of the Mll; Enl; CD19-Cre cohort that we kept under observation for 2 years. Postmortem examination of the 25 mice from the cohort was carried out and none were found to have abnormal haematopoietic organs or abnormal circulating cells. While Mll; Enl; Lmo2-Cre mice post-mortem examination showed splenomegaly, pale liver, kidney and bone marrow, that of the Mll; Enl; CD19-Cre mice, after 24 months of age, showed no significant macroscopic differences in haematopoietic organs compared to wild-type mice of the same age (Figure 2 ). Conversely, Mll; Enl; Lmo2-Cre samples showed invasion of the spleen and bone marrow by leukaemic cells with disruption of normal architecture and an extensive infiltration of tumour leukocytes into peripheral organs such as liver and kidneys.
The lack of tumorigenesis in the Mll; Enl; CD19-Cre mice could be the result of the chromosome territory of Mll and Enl alleles within the mouse B lymphoid cell population specifically precluding or reducing the frequency of chromosomal translocations between the two genes. Therefore, we investigated the presence of Mll and Enl or Mll and Af9 inter-chromosomal translocations in mice of the different groups using a quantitative genomic PCR assay dependent on the ability to amplify a product if Mll and Enl or Af9 sequences were adjacent to each other following translocation. Spleen DNA from asymptomatic (15 or 60-day postnatal) or leukaemic mice was prepared and used in the quantitative PCR analysis. In each case, at least five pups of appropriate genotypes were used. DNA from a Mll; Enl; Lmo2-Cre tumour cell culture (described previously; Drynan et al., 2005) was used as a 100% control. Analysis of the genomic frequency of the Mll-Enl or Mll-Af9 translocations in the different groups showed the presence of the translocation in all spleens, including the Mll; Enl; CD19-Cre translocators. The frequency varied depending on the cell of origin of the translocation as well on the age of the donor mouse (Figure 3a ). There is a correlation between the survival curve rates and latency periods of the different translocator groups. Interestingly, at 60 days after birth, both the Mll; Enl; Lck-Cre and CD19-Cre translocator mice show similar frequencies of translocations in spleen (2.1 Â 10 À3 and 2.4 Â 10 À3 respectively) but the latter do not develop any signs of disease during a 2-year period while 90% of the former developed haematopoietic neoplasms within 18 months. et al., 2003) were analysed over a period of 720 days. Data published previously for Mll; Af9; Lmo2-Cre mice are also shown as a dotted line (Drynan et al., 2005) . Mice were carefully observed from birth and post-mortem examination carried out at first signs of ill health. All mouse groups developed leukaemia except for mice of the Mll; Enl; CD19-Cre cohort that showed no haematological malignancies up to 720 days.
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The presence of Mll-Enl translocations in CD19-Cre translocator mice is accompanied by expression of the Mll-Enl fusion mRNA in the spleen of 18-month-old mice (Figure 3b ). Using nested reverse transcriptase-PCR with primers positioned in exon 10 of Mll and exon 2 of Enl, a product of the expected size for the fusion was detected and subsequently sequenced confirming the identity of the Mll-Enl fusion transcript and the correct splicing to give an Mll-Enl open reading frame. Thus, Mll-Enl translocations not only occur in the Mll; Enl; CD19-Cre mice cells but also the fusion mRNA is transcribed.
These data show that Mll-Enl chromosomal translocations do occur, and are expressed, in response to Cre expression from the CD19 allele. Confirmation of this normal haematopoiesis was obtained using flow cytometry ( Figure 4 ) and showed no perturbations in spleen or bone marrow aspirates of the Mll, Enl, CD19-Cre Figure 2 Histology of tissues from Mll; Enl; Lmo2-Cre and CD19-Cre mice. Haematoxylin-and eosin-stained sections of spleen, liver, kidney and bone marrow from a leukaemic Mll; Enl; Lmo2-Cre mouse (at time of death) and a 24-month-old Mll; Enl; CD19-Cre mouse were compared with control tissues from age-matched wild-type mice. No abnormal organ structure could be observed in the Mll; Enl; CD19-Cre mice compared with the wild-type control while the Mll; Enl; Lmo2-Cre samples show loss of normal architecture in spleen and bone marrow. All the sampled organs of the Mll; Enl; Lmo2-Cre mouse were heavily infiltrated with myeloid cells. Spleen, liver and kidney samples are magnified to Â 100, while bone marrows are Â 400.
Lineage specification in Mll-Enl translocator mice F Cano et al mice when compared to age-matched wild-type mice at 2 years of age. By contrast and in comparison, Mll; Enl; Lmo2-Cre mice developed leukaemia characterized by expression of the myeloid markers Mac-1 (CD11b) and Gr-1 (Ly-6G) as seen in the FACS analysis of both spleen and bone marrow (Figure 4) . Where CD19-Cre supplied the recombination signal for the Mll-Enl translocators, no pathological symptoms were observed in any mice. This implies that the Mll-Enl fusion mRNA cannot function as an oncogene in the B-cell lineage where CD19 is expressed and our data suggest the ineffectiveness of such translocation should it occur in that lineage in humans rather than a preclusion of the MLL-ENL translocations. Although the MLL-ENL fusion is found in patients with pro-B or pre-B acute lymphoblastic leukaemia and not in mature B-cell tumours and the inability of Mll-Enl to cause immature B-lineage tumours in our mouse model is probably a reflection of the CD19-Cre expression pattern. In this respect, it is noteworthy that our Mll-AF4 invertor model gave rise only to mature B-cell lymphomas when CD19-Cre was used (Metzler et al., 2006) , even though the MLL-AF4 translocation is predominant in immature B-cell leukaemias in infants and children.
It has been shown that Mll-Enl is an effective oncogene when chromosomal translocations are created in non-committed progenitors Drynan et al., 2005) or multipotent myeloid progenitors (Cozzio et al., 2003) . In the present work, we examined the potential oncogenicity of Mll-Enl in the B-cell compartment by restricting Cre recombinase expression under the influence of the CD19 promoter (Rickert et al., 1997) . When the Mll-Enl translocation was recreated in this cellular context, the mice remained leukaemia-free for over 24 months. The restriction of CD19-Cre expression to the B-cell lineage was confirmed by flow cytometry analysis of CD19-Cre mice crossed with mice carrying the ROSA-YFP loxP-STOP allele (Srinivas et al., 2001) verifying its restriction to the B-cell compartment (B220-positive cells; Supplementary Figure S1 online).
We have shown that, despite the absence of tumorigenesis, Mll-Enl chromosomal translocations do occur in CD19-Cre translocator mice, ruling out concerns that chromosome territory may inhibit translocations. Moreover, the Mll-Enl in-frame fusion transcripts were detectable. Our estimates of frequency of Mll-Enl translocations in the total spleen cells was around 4% at 2 years of age, despite which no leukaemias arose in this group. This number compares with the number observed in Mll; Af9; Lmo2-Cre translocators after only 2 months (Figure 3a) . Whether the number of Mll-Enl translocated cells reflects a long-lived population of translocation-positive cells or reflects the B cell pool CD19-Cre mice (seven mice, 24 months old). cDNA was synthesized and amplified in a nested PCR using primer sets positioned in Mll exon 10 and Enl exon 2. After 70 cycles, a product of the expected size for the fusion was detected. Samples were also analysed for the expression of b-actin as a loading control. All of the Mll; Enl; CD19-Cre mice express Mll-Enl fusion mRNA at 720 days.
Lineage specification in Mll-Enl translocator mice F Cano et al dynamics is not clear. An analogous situation was found with Mll-Af9 which, already having proved to be a potent inducer of myeloid leukaemias (Corral et al., 1996) , was unable to support tumorigenesis in T-lymphopoiesis (Drynan et al., 2005) . There are several possible reasons for the lack of Bcell tumours induced by Mll-Enl. The MLL protein associates with transcriptionally active promoters (Milne et al., 2002 (Milne et al., , 2005 . Therefore, MLL-ENL activity may be cell-type and differentiation-stage specific. In the B-cell lineage, the MLL-ENL target genes needed for its tumorigenic effect may not be actively transcribed and therefore the fusion protein is effectively impotent. It could also be the case that necessary Mll-Enl cofactors needed for the fusion to function do not exist or are not available in the B-cell lineage. Finally, it is possible that, in this particular cellular environment, Mll-Enl requires secondary mutations that do not occur, to be able to promote gross clonal expansion. Together, these considerations suggest that Mll-Enl alone cannot promote clonal proliferation in all cellular contexts, ruling out a simple oncogenic (non-instructive) role for this fusion protein.
Bloomfield CD, Archer KJ, Mrozek K, Lillington DM, Kaneko Y, Head DR et al. (2002) . 11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes Figure 4 Mll; Enl; CD19-Cre mice show a normal phenotype of cell surface marker expression. Spleen and bone marrow cells were prepared from Mll; Enl; Lmo2-Cre (at time of death) and CD19-Cre (24 months old) or from age-matched wild-type (WT) mice and stained with fluorescent antibodies. Antibodies used were FITC-CD4 plus PE-CD8a, FITC-Gr-1 (Ly-6G) plus PE-Mac-1 (CD11b) or FITC-B220 (CD45R) plus PE-Thy1.2. Cell surface marker analysis showed no increased populations in spleen or bone marrow aspirates of Mll; Enl; CD19-Cre mice when compared to the age-matched WT mice. The % of cells binding antibody is indicated in each sector of the FACS data sets.
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